009420.KS
009420.KS
KR7009420001
HANALL BIOPHARMA
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 55/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±64.7% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Largely moves in line with the broader market.

Beta (Market Relation)
0.93x
Defensive
Volatility (5Y p.a.)
64.7% p.a.
5-Year Horizon
Max Drawdown (5Y)
-51.3%
5-Year Horizon
Sharpe Ratio
0.23
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

Volatility Expansion (3Y > 5Y) High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — +26.4%
3 Years 73.1% -51.3% 0.05 +5.9%
5 Years 64.7% -51.3% 0.23 +17.2%
10 Years 62.0% -69.5% 0.12 +10.2%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Unprofitable business model: The company is currently generating net losses.
🔴 High valuation risk: Avg P/E of 376.9 (Elevated multiple compression risk)
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Elevated Short-Term Volatility: 3Y volatility (73.1%) is noticeably higher than the 5Y average (64.7%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (64.7% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -69.5% in the extended horizon.
ende